Pulmonary Arterial Hypertension Therapeutics

Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • Rep Id : TMRGL1181
  • Published On : Apr 2015
  • No. of Pages : 73
  • Category : Pharmaceutical

 
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions
      1.3.2 Sources
              1.3.2.1 Secondary Research
              1.3.2.2 Primary Research
      1.3.3 Models
1.4 List of Abbreviations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Pulmonary Arterial Hypertension Market (2013 & 2020)
2.2 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019 (USD Million)
2.3 Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2013 & 2020 (Value %)
 
Chapter 3 Global Pulmonary Arterial Hypertension (PAH) Market Overview
3.1 Introduction
3.2 Epidemiology
3.3 Annual Treatment Cost with Various PAH Drugs in the United States
3.4 Drivers
      3.4.1 Newly-approved therapeutic agents will significantly contribute to the growth of the PAH market
      3.4.2 Governments encouraging development of orphan drugs to propel growth of the PAH market
3.5 Restraints
      3.5.1 Patent expirations of major PAH drugs during the forecast period
3.6 Opportunities
      3.6.1 Emphasis on developing breakthrough therapy for the treatment of PAH
3.7 Even Impact Analysis
3.8 Competitive Landscape
      3.8.1 Global Pulmonary Arterial Hypertension Market Share Analysis, by Key Players, 2013 (Value %)
 
Chapter 4 Global Pulmonary Arterial Hypertension (PAH) Market Revenue, by Drug Class
4.1 Overview
      4.1.1 Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
      4.1.2 Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2013 & 2020 (Value %)
4.2 Prostacyclin and Prostacyclin Analogs
      4.2.1 Global Prostacyclin and Prostacyclin Analogs Market Revenue, 2012 – 2020 (USD Million)
      4.2.2 Historical Sales Data: Prostacyclin and Prostacyclin Analog Brands
4.3 Endothelin Receptor Antagonists (ERAs)
      4.3.1 Global Endothelin Receptor Antagonists Market Revenue, 2012 – 2020 (USD Million)
      4.3.2 Historical Sales Data: Endothelin Receptor Antagonist Brands
4.4 Phosphodiesterase 5 (PDE-5) Inhibitors
      4.4.1 Global Phosphodiesterase 5 Inhibitors Market Revenue, 2012 – 2020 (USD Million)
      4.4.2 Historical Sales Data: Phosphodiesterase 5 Inhibitor Brands
4.5 Soluble Guanylate Cyclase (sGC) Stimulators
      4.5.1 Global Soluble Guanylate Cyclase Stimulators Market Revenue, 2014 – 2020 (USD Million)
 
Chapter 5 Pipeline Analysis: Global Pulmonary Arterial Hypertension (PAH) Market
5.1 Overview
      5.1.1 Major Steps: Drug Development and Commercialization
5.2 Early-stage Drug Candidates (Phase I & Phase II)
      5.2.1 Pulmonary Arterial Hypertension: Phase I & Phase II Molecules
5.3 Late-stage Drug Candidates (Phase III & Registration Phase)
      5.3.1 Uptravi (selexipag)
              5.3.1.1 Global Uptravi (selexipag) Market Revenue, 2016 – 2020 (USD Million)
 
Chapter 6 Global Pulmonary Arterial Hypertension (PAH) Market, By Geography
6.1 Overview
      6.1.1 Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2012 – 2020 (USD Million)
6.2 North America
      6.2.1 North America Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
6.3 Europe
      6.3.1 Europe Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
6.4 Asia Pacific
      6.4.1 Asia Pacific Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
6.5 Rest of the World (RoW)
      6.5.1 RoW Pulmonary Arterial Hypertension Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 7 Recommendations
7.1 Focus on research and development
7.2 Collaboration
7.3 Targeting developing nations
 
Chapter 8 Company Profiles
8.1 Actelion Pharmaceuticals, Ltd.
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
8.2 Bayer HealthCare
      8.2.1 Company Overview
      8.2.2 Financial Overview
      8.2.3 Product Portfolio
      8.2.4 Business Strategies
      8.2.5 Recent Developments
8.3 Gilead Sciences, Inc.
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 GlaxoSmithKline plc
      8.4.1 Company Overview
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
      8.4.5 Recent Developments
8.5 Novartis International AG
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 Pfizer, Inc.
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 United Therapeutics Corporation
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments

List of Tables
 
TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Pulmonary Arterial Hypertension Market (2013 & 2020)
TABLE 3 Annual Treatment Cost with Various PAH Drugs in the United States
TABLE 4 Event Impact Analysis: Global PAH Market
TABLE 5 Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2012 – 2020 (USD Million)
TABLE 6 Historical Sales Data: Prostacyclin and Prostacyclin Analog Brands
TABLE 7 Historical Sales Data: Endothelin Receptor Antagonist Brands
TABLE 8 Historical Sales Data: Phosphodiesterase 5 Inhibitor Brands
TABLE 9 Pulmonary Arterial Hypertension: Phase I & Phase II Molecules
TABLE 10 Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2012 – 2020 (USD Million)
TABLE 11 List of Major Countries in North America
TABLE 12 List of Major Countries in Europe
TABLE 13 List of Major Countries in Asia Pacific
TABLE 14 List of Major Countries in Rest of the World

List of Figures
 
FIG. 1 Pulmonary Arterial Hypertension (PAH): Market Segmentation
FIG. 2 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019 (USD Million)
FIG. 3 Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Geography, 2013 & 2020 (Value %)
FIG. 4 Global Pulmonary Arterial Hypertension Market Share Analysis, by Key Players, 2013 (Value %)
FIG. 5 Comparative Analysis: Global Pulmonary Arterial Hypertension Market Revenue, by Drug Class, 2013 & 2020 (Value %)
FIG. 6 Global Prostacyclin and Prostacyclin Analogs Market Revenue, 2012 – 2020 (USD Million)
FIG. 7 Global Endothelin Receptor Antagonists Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Phosphodiesterase 5 Inhibitors Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 Global Soluble Guanylate Cyclase Stimulators Market Revenue, 2014 – 2020 (USD Million)
FIG. 10 Major Steps: Drug Development and Commercialization
FIG. 11 Global Uptravi (selexipag) Market Revenue, 2016 – 2020 (USD Million)
FIG. 12 North America Pulmonary Arterial Hypertension Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Europe Pulmonary Arterial Hypertension Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Asia Pacific Pulmonary Arterial Hypertension Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 RoW Pulmonary Arterial Hypertension Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Actelion Pharmaceuticals, Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 17 Bayer HealthCare: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 18 Gilead Sciences, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 GlaxoSmithKline plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Novartis International AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 United Therapeutics Corporation: Annual Revenue, 2011 – 2013 (USD Million)